BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30204961)

  • 21. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
    Sarkozy A; Carta C; Moretti S; Zampino G; Digilio MC; Pantaleoni F; Scioletti AP; Esposito G; Cordeddu V; Lepri F; Petrangeli V; Dentici ML; Mancini GM; Selicorni A; Rossi C; Mazzanti L; Marino B; Ferrero GB; Silengo MC; Memo L; Stanzial F; Faravelli F; Stuppia L; Puxeddu E; Gelb BD; Dallapiccola B; Tartaglia M
    Hum Mutat; 2009 Apr; 30(4):695-702. PubMed ID: 19206169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAF1-associated Noonan syndrome presenting antenatally with an abnormality of skull shape, subdural haematoma and associated with novel cerebral malformations.
    Hartill VL; Dillon MW; Warren DJ; Blyth M
    Clin Dysmorphol; 2017 Apr; 26(2):101-106. PubMed ID: 27753652
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome.
    Sana ME; Spitaleri A; Spiliotopoulos D; Pezzoli L; Preda L; Musco G; Ferrazzi P; Iascone M
    Am J Med Genet A; 2014 Aug; 164A(8):2069-73. PubMed ID: 24782337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Providing more evidence on LZTR1 variants in Noonan syndrome patients.
    Chinton J; Huckstadt V; Mucciolo M; Lepri F; Novelli A; Gravina LP; Obregon MG
    Am J Med Genet A; 2020 Feb; 182(2):409-414. PubMed ID: 31825158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
    Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
    Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies.
    Komatsuzaki S; Aoki Y; Niihori T; Okamoto N; Hennekam RC; Hopman S; Ohashi H; Mizuno S; Watanabe Y; Kamasaki H; Kondo I; Moriyama N; Kurosawa K; Kawame H; Okuyama R; Imaizumi M; Rikiishi T; Tsuchiya S; Kure S; Matsubara Y
    J Hum Genet; 2010 Dec; 55(12):801-9. PubMed ID: 20882035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurofibromatosis-Noonan Syndrome: A Possible Paradigm of the Combination of Genetic and Epigenetic Factors.
    Yapijakis C; Pachis N; Voumvourakis C
    Adv Exp Med Biol; 2017; 987():151-159. PubMed ID: 28971455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The face of Noonan syndrome: Does phenotype predict genotype.
    Allanson JE; Bohring A; Dörr HG; Dufke A; Gillessen-Kaesbach G; Horn D; König R; Kratz CP; Kutsche K; Pauli S; Raskin S; Rauch A; Turner A; Wieczorek D; Zenker M
    Am J Med Genet A; 2010 Aug; 152A(8):1960-6. PubMed ID: 20602484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Mutation on RAF1 in Association with Fetal Findings Suggestive of Noonan Syndrome.
    Kneitel AW; Norby A; Vettraino I; Treadwell MC
    Fetal Pediatr Pathol; 2015; 34(6):361-4. PubMed ID: 26467173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
    Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
    Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noonan syndrome with RAF1 gene mutations in a newborn with cerebral haemorrhage.
    Lan J; Zeng T; Liu S; Lan J; Qian L
    Eur J Med Res; 2022 Aug; 27(1):146. PubMed ID: 35953836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
    Alhumaid MS; Dasouki MJ; Ahmed SO; AbalKhail H; Hagos S; Wakil S; Hashmi SK
    Acta Haematol; 2020; 143(6):583-593. PubMed ID: 32541138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prenatal diagnosis of hypoplastic left heart syndrome associated with Noonan Syndrome and de novo RAF1 mutation.
    Schulz S; Fröber R; Kraus C; Schneider U
    Prenat Diagn; 2012 Oct; 32(10):1016-8. PubMed ID: 22821648
    [No Abstract]   [Full Text] [Related]  

  • 38. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes.
    Lee BH; Kim JM; Jin HY; Kim GH; Choi JH; Yoo HW
    J Pediatr; 2011 Dec; 159(6):1029-35. PubMed ID: 21784453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
    Zebisch A; Haller M; Hiden K; Goebel T; Hoefler G; Troppmair J; Sill H
    Leukemia; 2009 Jun; 23(6):1049-53. PubMed ID: 19357705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.